[go: up one dir, main page]

WO2008109437A3 - Compositions et traitements pour des troubles liés à des crises - Google Patents

Compositions et traitements pour des troubles liés à des crises Download PDF

Info

Publication number
WO2008109437A3
WO2008109437A3 PCT/US2008/055495 US2008055495W WO2008109437A3 WO 2008109437 A3 WO2008109437 A3 WO 2008109437A3 US 2008055495 W US2008055495 W US 2008055495W WO 2008109437 A3 WO2008109437 A3 WO 2008109437A3
Authority
WO
WIPO (PCT)
Prior art keywords
phenylpyridazine
derivatives
compositions
related disorders
treating seizure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/055495
Other languages
English (en)
Other versions
WO2008109437A2 (fr
Inventor
D. Martin Watterson
Linda J. Van Eldik
Mark S. Wainwright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Priority to EP08731122A priority Critical patent/EP2131839A2/fr
Priority to US12/529,357 priority patent/US20100210590A1/en
Priority to AU2008223066A priority patent/AU2008223066A1/en
Priority to JP2009551873A priority patent/JP2010520223A/ja
Priority to CA002679917A priority patent/CA2679917A1/fr
Publication of WO2008109437A2 publication Critical patent/WO2008109437A2/fr
Anticipated expiration legal-status Critical
Publication of WO2008109437A3 publication Critical patent/WO2008109437A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des utilisations thérapeutiques et/ou prophylactiques de composés pyridazine et des compositions pharmaceutiques contenant un ou plusieurs de ces composés en tant que composant actif pour traiter un trouble caractérisé par des perturbations de conduction, des électroconvulsions et/ou des crises, en particulier l'épilepsie, plus particulièrement l'épilepsie pédiatrique. Dans un aspect de l'invention, le composé pyridazine a la formule Ia ou Ib dans laquelle R1, R2, R3, R4, R5, R6 et R7 sont tels que définis dans la description.
PCT/US2008/055495 1995-09-27 2008-02-29 Compositions et traitements pour des troubles liés à des crises Ceased WO2008109437A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP08731122A EP2131839A2 (fr) 2007-03-02 2008-02-29 Compositions et traitements pour des troubles liés à des crises
US12/529,357 US20100210590A1 (en) 1995-09-27 2008-02-29 Compositions and treatments for seizure-related disorders
AU2008223066A AU2008223066A1 (en) 2007-03-02 2008-02-29 Compositions comprising derivatives of 3 -phenylpyridazine for treating seizure-related disorders
JP2009551873A JP2010520223A (ja) 2007-03-02 2008-02-29 発作関連障害のための組成物および方法
CA002679917A CA2679917A1 (fr) 2007-03-02 2008-02-29 Compositions et traitements pour des troubles lies a des crises

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90460607P 2007-03-02 2007-03-02
US60/904,606 2007-03-02
US438507P 2007-11-27 2007-11-27
US60/004,385 2007-11-27

Publications (2)

Publication Number Publication Date
WO2008109437A2 WO2008109437A2 (fr) 2008-09-12
WO2008109437A3 true WO2008109437A3 (fr) 2009-11-19

Family

ID=39345468

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055495 Ceased WO2008109437A2 (fr) 1995-09-27 2008-02-29 Compositions et traitements pour des troubles liés à des crises

Country Status (5)

Country Link
EP (1) EP2131839A2 (fr)
JP (1) JP2010520223A (fr)
AU (1) AU2008223066A1 (fr)
CA (1) CA2679917A1 (fr)
WO (1) WO2008109437A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018563A1 (fr) 2001-08-31 2003-03-06 Northwestern University Composition anti-inflammatoire et inhibitrice de la proteine kinase et methode d'utilisation
JP2008518955A (ja) 2004-11-02 2008-06-05 ノースウェスタン ユニバーシティ ピリダジン化合物および方法
CN101087766B (zh) 2004-11-02 2011-09-07 西北大学 哒嗪化合物、组合物和方法
EP2015750A2 (fr) 2006-04-28 2009-01-21 Northwestern University Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinestérase
JP2009535344A (ja) 2006-04-28 2009-10-01 ノースウェスタン ユニバーシティ 神経炎症性疾患の処置のためのピリダジン化合物を含む処方物
AR072899A1 (es) 2008-08-07 2010-09-29 Merck Sharp & Dohme Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad.
AU2009308982A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Pyridazine carboxamide orexin receptor antagonists
JP5635991B2 (ja) 2008-10-30 2014-12-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． イソニコチンアミドオレキシン受容体アンタゴニスト

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0094038A1 (fr) * 1982-05-08 1983-11-16 Hoechst Aktiengesellschaft 3-Amino-6-aryl-1,2,4-triazolo(4,3-b)pyridazines, leur préparation et leur utilisation
US4654343A (en) * 1985-10-31 1987-03-31 American Cyanamid Company N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas
US4710499A (en) * 1981-08-11 1987-12-01 Sanofi New derivatives of pyridazine active on the central nervous system
US20060073472A1 (en) * 2001-08-31 2006-04-06 Watterson D M Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
WO2007127448A2 (fr) * 2006-04-28 2007-11-08 Northwestern University Sels de composés de pyridazine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710499A (en) * 1981-08-11 1987-12-01 Sanofi New derivatives of pyridazine active on the central nervous system
EP0094038A1 (fr) * 1982-05-08 1983-11-16 Hoechst Aktiengesellschaft 3-Amino-6-aryl-1,2,4-triazolo(4,3-b)pyridazines, leur préparation et leur utilisation
US4654343A (en) * 1985-10-31 1987-03-31 American Cyanamid Company N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas
US20060073472A1 (en) * 2001-08-31 2006-04-06 Watterson D M Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
WO2007127448A2 (fr) * 2006-04-28 2007-11-08 Northwestern University Sels de composés de pyridazine

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; June 1985 (1985-06-01), CHAMBON J P ET AL: "CM 40907: a structurally novel anticonvulsant in mice, rats and baboons.", XP002523988, Database accession no. NLM2989499 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; March 1986 (1986-03-01), HALLOT A ET AL: "Synthesis and activity of 6-aryl-3-(hydroxypolymethyleneamino)pyrida zines in animal models of epilepsy.", XP002523989, Database accession no. NLM3950916 *
HU ET AL: "Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 17, no. 2, 11 January 2007 (2007-01-11), pages 414 - 418, XP005827244, ISSN: 0960-894X *
JOURNAL OF MEDICINAL CHEMISTRY MAR 1986, vol. 29, no. 3, March 1986 (1986-03-01), pages 369 - 375, ISSN: 0022-2623 *
SOMER-MOLINA K C ET AL: "Glial activation links early-life seizures and long-term neurologic dysfunction: evidence using a small molecule inhibitor of proinflammatory cytokine upregulation", EPILEPSIA, RAVEN PRESS LTD., NEW YORK, vol. 48, no. 9, 1 September 2007 (2007-09-01), pages 1785 - 1800, XP008085830, ISSN: 0013-9580 *
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS JUN 1985, vol. 233, no. 3, June 1985 (1985-06-01), pages 836 - 844, ISSN: 0022-3565 *
VEZZANI ANNAMARIA ET AL: "Brain inflammation in epilepsy: experimental and clinical evidence.", EPILEPSIA NOV 2005, vol. 46, no. 11, November 2005 (2005-11-01), pages 1724 - 1743, XP002523987, ISSN: 0013-9580 *
VEZZANI ANNAMARIA ET AL: "Functional role of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis.", EPILEPSIA 2002, vol. 43 Suppl 5, 2002, pages 30 - 35, XP002523986, ISSN: 0013-9580 *
VEZZANI, A.: "Brain Inflammation and Seizures", EPILEPSY CURRENTS, vol. 4, no. 2, 26 February 2004 (2004-02-26), pages 73 - 75, XP002523985 *

Also Published As

Publication number Publication date
JP2010520223A (ja) 2010-06-10
AU2008223066A1 (en) 2008-09-12
CA2679917A1 (fr) 2008-09-12
EP2131839A2 (fr) 2009-12-16
WO2008109437A2 (fr) 2008-09-12

Similar Documents

Publication Publication Date Title
WO2008109437A3 (fr) Compositions et traitements pour des troubles liés à des crises
WO2007140439A3 (fr) Nouveaux composés constituant des ligands de récepteurs cannabinoïdes et utilisations de ces composés
WO2009110985A3 (fr) Composés amides, compositions à base de ces composés et leurs utilisations
WO2007133637A3 (fr) Dérivés d'amides en tant que ligands de canal ionique et compositions pharmaceutiques et méthodes d'utilisation desdits dérivés
MX2009012163A (es) Hetarilanilinas como moduladores para beta-amiloide.
WO2010017545A3 (fr) Composés de triazole qui modulent l'activité hsp90
WO2010033168A3 (fr) Composés amides, compositions et utilisations des composés et compositions
WO2010028192A8 (fr) Compositions comprenant des dérivés d’acide 6-aminohexanoïque utilisées comme inhibiteurs de hdac
WO2008001195A3 (fr) Nouveaux procédés de synthèse d'inhibiteurs de dpp iv
WO2010022055A3 (fr) Inhibiteurs de canaux sodiques sensibles au potentiel
TW200744586A (en) Therapeutic compounds
WO2008132139A3 (fr) Nouveaux dérivés hétérocycliques utiles pour le traitement des troubles du système nerveux central
WO2007138282A3 (fr) Nouveaux composés
WO2010026436A3 (fr) Composés pharmaceutiques
WO2009016410A3 (fr) Composés chimiques 831
GEP20156330B (en) Aryl-and heteroarylcarbonyl derivatives of hexahydro- indenopyridine and octahydrobenzoquinoline
WO2010033701A3 (fr) Inhibiteurs de la sphingosine kinase 1
TW200612958A (en) Substituted imidazole derivatives
PL2150530T3 (pl) Podstawione pochodne sulfonamidu
WO2010033543A3 (fr) Composés inédits utilisables en tant que ligands des récepteurs cannabinoïdes
WO2007100758A3 (fr) Dérivés amides en tant que ligands de canal ionique et compositions pharmaceutiques et procédés d'utilisation de tels dérivés
WO2008086122A3 (fr) Dérivés cyclisés en tant qu'inhibiteurs d'eg-5
WO2011159124A3 (fr) Nouveau dérivé de benzoxazole présentant une activité inhibitrice contre l'interleukine 6, procédé pour le préparer, et composition pharmaceutique le contenant
WO2011149993A3 (fr) Octahydrocyclopenta [c] pyrroles substitués utilisés en tant que modulateurs des canaux calciques
EP2215054B8 (fr) Dérivés amide à titre de ligands des canaux ioniques et compositions pharmaceutiques et procédés d'utilisation correspondants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08731122

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009551873

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2679917

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008223066

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008731122

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008223066

Country of ref document: AU

Date of ref document: 20080229

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12529357

Country of ref document: US